Item talk:Q167209: Difference between revisions

From geokb
No edit summary
No edit summary
 
Line 1: Line 1:
{
{
   "id": "https://openalex.org/T11157",
   "OpenAlex": {
  "display_name": "Genomic Aberrations and Treatment of Chronic Lymphocytic Leukemia",
    "cited_by_count": 1151188,
  "description": "This cluster of papers focuses on the genomic aberrations, treatment strategies, and prognostic factors associated with chronic lymphocytic leukemia (CLL). It covers topics such as the use of BTK inhibitors (e.g., Ibrutinib), the role of rituximab, TP53 mutations, and the impact of immunoglobulin mutations. Additionally, it explores therapeutic targets and outcomes in patients with Waldenstr\u00f6m macroglobulinemia.",
    "created_date": "2024-01-23",
  "keywords": [
    "description": "This cluster of papers focuses on the genomic aberrations, treatment strategies, and prognostic factors associated with chronic lymphocytic leukemia (CLL). It covers topics such as the use of BTK inhibitors (e.g., Ibrutinib), the role of rituximab, TP53 mutations, and the impact of immunoglobulin mutations. Additionally, it explores therapeutic targets and outcomes in patients with Waldenstr\u00f6m macroglobulinemia.",
    "Chronic Lymphocytic Leukemia",
    "display_name": "Genomic Aberrations and Treatment of Chronic Lymphocytic Leukemia",
     "Genomic Aberrations",
     "domain": {
    "BTK Inhibitors",
      "id": "https://openalex.org/domains/4",
    "Rituximab",
      "display_name": "Health Sciences"
    "Ibrutinib",
    "Prognostic Factors",
    "TP53 Mutation",
    "Waldenstr\u00f6m Macroglobulinemia",
    "Immunoglobulin Mutation",
    "Therapeutic Targets"
  ],
  "ids": {
    "openalex": "https://openalex.org/T11157",
    "wikipedia": "https://en.wikipedia.org/wiki/Chronic_lymphocytic_leukemia"
  },
  "subfield": {
    "id": "https://openalex.org/subfields/2716",
    "display_name": "Genetics"
  },
  "field": {
    "id": "https://openalex.org/fields/27",
    "display_name": "Medicine"
  },
  "domain": {
    "id": "https://openalex.org/domains/4",
    "display_name": "Health Sciences"
  },
  "siblings": [
    {
      "id": "https://openalex.org/T13738",
      "display_name": "CHARGE Syndrome and Related Genetic Disorders"
     },
     },
     {
     "field": {
       "id": "https://openalex.org/T12199",
       "id": "https://openalex.org/fields/27",
       "display_name": "Diagnosis and Management of Hereditary Hemorrhagic Telangiectasia"
       "display_name": "Medicine"
     },
     },
     {
     "id": "https://openalex.org/T11157",
       "id": "https://openalex.org/T12400",
    "ids": {
       "display_name": "Gene Therapy for Spinal Muscular Atrophy"
       "openalex": "https://openalex.org/T11157",
       "wikipedia": "https://en.wikipedia.org/wiki/Chronic_lymphocytic_leukemia"
     },
     },
     {
     "keywords": [
       "id": "https://openalex.org/T10554",
      "Chronic Lymphocytic Leukemia",
      "display_name": "Genetic and Clinical Aspects of Hemoglobin Disorders"
      "Genomic Aberrations",
      "BTK Inhibitors",
      "Rituximab",
      "Ibrutinib",
      "Prognostic Factors",
      "TP53 Mutation",
      "Waldenstr\u00f6m Macroglobulinemia",
      "Immunoglobulin Mutation",
      "Therapeutic Targets"
    ],
    "siblings": [
      {
        "id": "https://openalex.org/T13738",
        "display_name": "CHARGE Syndrome and Related Genetic Disorders"
      },
      {
        "id": "https://openalex.org/T12199",
        "display_name": "Diagnosis and Management of Hereditary Hemorrhagic Telangiectasia"
      },
      {
        "id": "https://openalex.org/T12400",
        "display_name": "Gene Therapy for Spinal Muscular Atrophy"
       },
      {
        "id": "https://openalex.org/T10554",
        "display_name": "Genetic and Clinical Aspects of Hemoglobin Disorders"
      },
      {
        "id": "https://openalex.org/T10129",
        "display_name": "Gliomas"
      },
      {
        "id": "https://openalex.org/T11917",
        "display_name": "Hereditary Angioedema: Molecular Mechanisms and Clinical Management"
      },
      {
        "id": "https://openalex.org/T11628",
        "display_name": "Molecular Pathogenesis of Myeloproliferative Disorders"
      },
      {
        "id": "https://openalex.org/T10176",
        "display_name": "Multipotent Mesenchymal Stem Cells"
      }
    ],
    "subfield": {
      "id": "https://openalex.org/subfields/2716",
      "display_name": "Genetics"
     },
     },
     {
     "updated_date": "2024-08-19T06:09:29.975916",
      "id": "https://openalex.org/T10129",
     "works_count": 87734,
      "display_name": "Gliomas"
     "oa_id": "T11157"
    },
  }
    {
      "id": "https://openalex.org/T11917",
      "display_name": "Hereditary Angioedema: Molecular Mechanisms and Clinical Management"
    },
     {
      "id": "https://openalex.org/T11628",
      "display_name": "Molecular Pathogenesis of Myeloproliferative Disorders"
    },
     {
      "id": "https://openalex.org/T10176",
      "display_name": "Multipotent Mesenchymal Stem Cells"
    }
  ],
  "works_count": 87782,
  "cited_by_count": 1153009,
  "updated_date": "2024-08-26T05:17:28.864777",
  "created_date": "2024-01-23"
}
}

Latest revision as of 21:11, 12 September 2024

{

 "OpenAlex": {
   "cited_by_count": 1151188,
   "created_date": "2024-01-23",
   "description": "This cluster of papers focuses on the genomic aberrations, treatment strategies, and prognostic factors associated with chronic lymphocytic leukemia (CLL). It covers topics such as the use of BTK inhibitors (e.g., Ibrutinib), the role of rituximab, TP53 mutations, and the impact of immunoglobulin mutations. Additionally, it explores therapeutic targets and outcomes in patients with Waldenstr\u00f6m macroglobulinemia.",
   "display_name": "Genomic Aberrations and Treatment of Chronic Lymphocytic Leukemia",
   "domain": {
     "id": "https://openalex.org/domains/4",
     "display_name": "Health Sciences"
   },
   "field": {
     "id": "https://openalex.org/fields/27",
     "display_name": "Medicine"
   },
   "id": "https://openalex.org/T11157",
   "ids": {
     "openalex": "https://openalex.org/T11157",
     "wikipedia": "https://en.wikipedia.org/wiki/Chronic_lymphocytic_leukemia"
   },
   "keywords": [
     "Chronic Lymphocytic Leukemia",
     "Genomic Aberrations",
     "BTK Inhibitors",
     "Rituximab",
     "Ibrutinib",
     "Prognostic Factors",
     "TP53 Mutation",
     "Waldenstr\u00f6m Macroglobulinemia",
     "Immunoglobulin Mutation",
     "Therapeutic Targets"
   ],
   "siblings": [
     {
       "id": "https://openalex.org/T13738",
       "display_name": "CHARGE Syndrome and Related Genetic Disorders"
     },
     {
       "id": "https://openalex.org/T12199",
       "display_name": "Diagnosis and Management of Hereditary Hemorrhagic Telangiectasia"
     },
     {
       "id": "https://openalex.org/T12400",
       "display_name": "Gene Therapy for Spinal Muscular Atrophy"
     },
     {
       "id": "https://openalex.org/T10554",
       "display_name": "Genetic and Clinical Aspects of Hemoglobin Disorders"
     },
     {
       "id": "https://openalex.org/T10129",
       "display_name": "Gliomas"
     },
     {
       "id": "https://openalex.org/T11917",
       "display_name": "Hereditary Angioedema: Molecular Mechanisms and Clinical Management"
     },
     {
       "id": "https://openalex.org/T11628",
       "display_name": "Molecular Pathogenesis of Myeloproliferative Disorders"
     },
     {
       "id": "https://openalex.org/T10176",
       "display_name": "Multipotent Mesenchymal Stem Cells"
     }
   ],
   "subfield": {
     "id": "https://openalex.org/subfields/2716",
     "display_name": "Genetics"
   },
   "updated_date": "2024-08-19T06:09:29.975916",
   "works_count": 87734,
   "oa_id": "T11157"
 }

}